Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (8302)	1/16/1999 1:33:00 AM
From: aknahow	Read Replies (3) \| Respond to of 17367

Murphy, basically confirms the concept that total deaths are important key to ending the trial. When the unknown number is reached DSMB will tell XOMA to stop the trial and start talking to the FDA. Ten days after trial is halted the data on mortality by group, or leg will be available. He spent a lot of time on the hotline talking about XOMA but never mentioned what I believe is the real significance of the need to continue the trial. Which again is that deaths in total, have been less than "expected", and while this is not proof Neuprex works, it at least means continuation of the trial is not in itself proof Neuprex results are less than expected. One could argue that the better Neuprex works the more it would be necessary to continue the trial. I swear, I am not going to post more about this. People will either understand it, or not. Would like to see Robert S explain why none of the above makes any sense, but of course even if it does remember there is no market for BPI anyway.<g>